Monday, August 25, 2025 3:42:53 PM
Drugrunner, It is informative. The relentless cycle of 24/7/365 negativity/anger, shorts in shareholders clothing, FUD, years, so much volume posts, a form of fake-goodwill-bashing... All of that means only one thing.
Any substance these Short's arguments and tactics originally had, if any, has all been spent now, all played out.
- Their shorting and spoofing of shares has been absorbed by patient Retail buying.
- NWBO's R&D "risk phase" has been resolved. The landmark global Phase 3 GBM trial was a resounding success and as is supported by the JAMA publication and authored by 70+ oncologists
- Allegations of bad management has been debunked. Instead there's been strategic acquisitions of Flaskworks and Roswell, Sawston state-of-the-art mfg facility, and the vision of Franchise / global immunotherapy platform.
- Most importantly, the DCVax-L MAA train has already left the station and has now obtained sufficient speed and momentum to deliver a giant breakthrough approval.
So the clarity in all this might possibly be:
- the Short's are spent
- incoming new money investors are poised to step in
- the DCVax platform is positioned to transform the future of cancer therapy
- and NWBO is a real emerging unicorn company possibility offering a rare asymmetric risk-reward investment opportunity, both near and long term.
Any substance these Short's arguments and tactics originally had, if any, has all been spent now, all played out.
- Their shorting and spoofing of shares has been absorbed by patient Retail buying.
- NWBO's R&D "risk phase" has been resolved. The landmark global Phase 3 GBM trial was a resounding success and as is supported by the JAMA publication and authored by 70+ oncologists
- Allegations of bad management has been debunked. Instead there's been strategic acquisitions of Flaskworks and Roswell, Sawston state-of-the-art mfg facility, and the vision of Franchise / global immunotherapy platform.
- Most importantly, the DCVax-L MAA train has already left the station and has now obtained sufficient speed and momentum to deliver a giant breakthrough approval.
So the clarity in all this might possibly be:
- the Short's are spent
- incoming new money investors are poised to step in
- the DCVax platform is positioned to transform the future of cancer therapy
- and NWBO is a real emerging unicorn company possibility offering a rare asymmetric risk-reward investment opportunity, both near and long term.
Bullish
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
